缬沙坦治疗充血性心力衰竭临床观察

目的 :探讨缬沙坦治疗充血性心力衰竭 (CHF)临床疗效。方法 :采用随机、单盲自身对照及组间对照 ,将 5 0例CHF分为缬沙坦组 (2 5例 ) ,服用缬沙坦 80mg/d ;常规治疗组 (对照组 ,2 5例 ) ,疗程均为 18周 ,观察两组治疗前后临床疗效、左室射血分数 (LVEF)、左室舒张末期容积 (EDV)、左室收缩末期容积 (ESV)、6min步行试验及实验室参数的变化。结果 :治疗后缬沙坦组临床显效率 4 8.0 % ,有效率 4 4 .0 % ,无效率 8.0 % ,对照组分别为 36 .0 %、4 0 .0 %、2 4 .0 % ,治疗后与治疗前相比两组LVEF、EDV、ESV、6min步行试验相关参数均有显著改善(P <0 .0 1) ,缬沙坦组与对照组组间比较差异有非常显著意义 (P <0 .0 1) ;血生化两组治疗前后及组间比较差异均无显著性意义 (P >0 .0 5 )。结论 :缬沙坦治疗CHF疗效肯定 ,优于常规治疗 ,值得临床推广应用

The observation of effect of valsartan on the patients with congestive heart failure

Objective: The aim of this study is to observe the effects of valsartan on patients with congestive heart failure.Method: Using random and single blind contrast during the period of 18 weeks, we divided 50 patients with congestive heart failure into valsartan group(n=25)and the control group(n=25). In addition to the evaluation of clinical effect, LVEF, 6 min walk trial and the other biochemistry parameters were measured. Result: The clinical prognosis of the patients in the vaisartan group were better than that of the patients in the control group, and LVEF, LEDV, LESY and 6 min walk trail of the patients in the valsartan group were all siganificangly ameliorated compared with those of the patients before treatment or in the control group or after treat ment (all P< 0.01 ). No siganificant difference in biochemistry parameters could be found between two groups(P> 0.05 ).Conclusion: Valsartan possesses obvious effect in treating patients with congestive heart failure, and is valuable to be spreaded broadly in clinic.